SCHEDULE 13G/A: JPMorgan Chase & Co. Divests Entire Stake in Intra-Cellular Therapies, Inc.

Sentiment:

Beneficial Ownership Report 5 June 2025 5:42 PM

JPMorgan Chase & Co. has filed an amended Schedule 13G, reporting zero beneficial ownership in Intra-Cellular Therapies, Inc. as of May 30, 2025.

Worse than expectedJPMorgan Chase & Co. now reports 0.0% beneficial ownership in Intra-Cellular Therapies, Inc., indicating a complete divestment from their previous position, which is generally perceived as a negative signal for the issuer.

Summary

JPMorgan Chase & Co. filed an Amendment No. 1 to its Schedule 13G regarding its beneficial ownership in Intra-Cellular Therapies, Inc.
As of May 30, 2025, JPMorgan Chase & Co. reports 0.00 shares beneficially owned, representing 0.0% of Intra-Cellular Therapies, Inc.'s Common Stock.
The filing classifies JPMorgan Chase & Co. as a parent holding company or control person.
The securities were certified as acquired and held in the ordinary course of business, not for the purpose of changing or influencing the control of the issuer.
Several JPMorgan subsidiaries, including J.P. Morgan Trust Company of Delaware and J.P. Morgan Securities LLC, were identified as entities that previously acquired the security.

Sentiment

Score: 4

Explanation: The filing indicates a complete divestment by a major financial institution, which can be perceived as a lack of institutional confidence or a rebalancing of portfolios, generally leading to a slightly negative sentiment for the issuer's stock.

Future Outlook

Management Comments

"The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities."

Industry Context

This filing is a routine disclosure of institutional ownership changes, reflecting a major financial institution's decision to exit its position in a pharmaceutical company. It does not provide broader industry trends or specific reasons for the divestment.

Stakeholder Impact

Shareholders: May interpret the complete divestment by a major institution as a negative signal, potentially influencing their investment decisions and the company's stock price.

Key Dates

Date	Description
05/30/2025	Date of event which requires filing of this statement, indicating the effective date of the reported ownership change.
06/05/2025	Date the Schedule 13G Amendment No. 1 was signed by JPMorgan Chase & Co.

Keywords

Intra-Cellular Therapies Inc., JPMorgan Chase & Co., Schedule 13G, beneficial ownership, common stock, SEC filing, institutional ownership, divestment

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.